Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    GABA molecular structure

    GABA Stats & Data

    PubChem
    MW103.12
    FormulaC4H9NO2
    LogP-3.2
    IUPAC4-aminobutanoic acid
    InChIKeyBTCSSZJGUNDROE-UHFFFAOYSA-N
    Chemical Class GABA analogue
    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    State Solid

    Description

    The most common inhibitory neurotransmitter in the central nervous system.

    Measured Affinities

    Guide to PHARMACOLOGY

    Measured binding and functional data for GABA, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

    Target Action Measure Value Concentration Species Source
    GABAB receptor Gabbr1|Gabbr2|Kctd8|Kctd12|Kctd16 Full agonist pIC50 8.3 5.01 nM Rat —
    GABAB receptor GABBR1|GABBR2|KCTD8|KCTD12|KCTD16 Full agonist pKi — — Human —
    GABAB1 Gabbr1 Full agonist pIC50 — — Rat PMID 9069281
    Glycine Receptor (All subtypes) Partial agonist pEC50 — — Rat —

    Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

    Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

    Toxicity

    PubChem

    Carcinogenicity

    No indication of carcinogenicity to humans (not listed by IARC).

    Health effects (PubChem excerpts)

    Chronically high levels of GABA are associated with at least 5 inborn errors of metabolism including: D-2-Hydroxyglutaric Aciduria, 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency, GABA-Transaminase Deficiency, Homocarnosinosis and Succinic semialdehyde dehydrogenase deficiency.

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 3d Half tolerance 37d Baseline ~60d

    Experience Report Analysis

    Erowid
    10 Reports
    6 Single-substance
    2003–2021 Date Range
    7 With Age Data

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 10 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 8 of 10
    • Female 1 of 10
    • Not Specified 1 of 10

    Age Distribution

    Reports Over Time

    Real-World Dose Distribution

    Erowid

    From 11 of 17 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Oral (n=11)

    Median: 1000.0mg 25th: 400.0mg 75th: 2000.0mg 90th: 4000.0mg

    Form / Preparation

    Most common forms and preparations, as a share of the 6 reports that give one

    Too few reports for bars: these forms come from 6 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Powder / Crystals 4 of 6
    ← Back to GABA